Long-term study of zasocitinib for children with plaque psoriasis
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests a daily pill (zasocitinib) for children and teens with moderate to severe plaque psoriasis that hasn't been controlled by other treatments. It aims to see if the pill can safely improve skin symptoms over a long period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child or teen aged 4 to 17 years old (for ages 12–17, must weigh at least 88 pounds)
- Diagnosed with plaque psoriasis for at least 6 months, with stable symptoms (no major flares)
- Moderate to severe psoriasis covering at least 10% of the body (like the size of 10 palms)
- Must be a candidate for light therapy or stronger medications (like pills or shots)
- No active infections (like tuberculosis, herpes, or serious infections) and must be up to date on childhood vaccines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug (ZP9830) to see if it is safe and works well for people with plaque psoriasis. You would receive the treatment for 8 weeks, and the study will check how your skin responds.
This trial tests a new oral medication, CS32582, for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing skin symptoms like redness, thickness, and scaling.
This study checks whether deucravacitinib works well and is safe in children and teens with moderate to severe plaque psoriasis. It also looks at drug levels in the body to help understand how the treatment behaves over time.
This study tests an investigational medication (zasocitinib) taken by mouth to reduce joint pain, swelling, and skin symptoms in adults with psoriatic arthritis. It is for people whose symptoms have not improved enough with standard treatments.
This study is for people with psoriatic arthritis who have already completed a year-long treatment with zasocitinib or a similar medicine in a previous study. It tests whether continuing to take zasocitinib remains safe and helpful over a longer time.
This study tests an experimental pill called zasocitinib for people with moderate-to-severe psoriasis on the palms and soles. It aims to reduce symptoms and improve quality of life.
Hear when a new Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.